| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma |
NCT05474755: To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection |
|
|
| Completed | 3 | 591 | RoW | GP681 40mg, Placebo | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Influenza | 04/23 | 10/23 | | |
NCT06573008: Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications |
|
|
| Not yet recruiting | 3 | 328 | NA | GP681 40mg, GP681 Simulant | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Influenza, Human | 12/25 | 12/25 | | |
NCT06574503: Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza |
|
|
| Not yet recruiting | 3 | 748 | NA | GP681 40mg, GP681 Simulant | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Influenza | 07/27 | 12/27 | | |
NCT05789342: A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers |
|
|
| Completed | 1 | 54 | RoW | GP681, Rosuvastatin, Digoxin, Itraconazole, Oseltamivir | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Healthy Volunteers | 09/23 | 10/23 | | |
NCT05814926: GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers |
|
|
| Completed | 1 | 24 | RoW | GP681 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Healthy Volunteers, Hepatic Impairment | 08/23 | 10/23 | | |
NCT06643156: Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension |
|
|
| Recruiting | 1 | 40 | RoW | GP681 10mg/20mg/40mg | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Influenza | 02/25 | 03/25 | | |
NCT06678542: Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects |
|
|
| Not yet recruiting | 1 | 36 | NA | GP681 tablet, Reference treatment, GP681 Powder for Oral Suspension, Test Treatment | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Healthy Participants | 12/24 | 01/25 | | |
